
|Videos|July 24, 2017
Tackling Endocrine Resistance in Breast Cancer
Author(s)Ingrid A. Mayer, MD, MSCI
This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.
Advertisement
In this video, Ingrid A. Mayer, MD, MSCI, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses mechanisms of acquired and upfront endocrine resistance in estrogen receptor (ER)-positive breast cancer as well as research into strategies for overcoming these types of resistance, including targeting the mTOR and PI3K pathways.
Mayer spoke on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
2
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
3
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5

























































